- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03897491
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
November 15, 2023 updated by: photonamic GmbH & Co. KG
Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed supratentorial IDH wild-type glioblastoma.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marcus Stocker, Dr.
- Phone Number: +49(0)4101/7853-953
- Email: m.stocker@photonamic.de
Study Contact Backup
- Name: Friederike Haubenschild
- Email: f.haubenschild@photonamic.de
Study Locations
-
-
-
Köln, Germany, 50924
- Not yet recruiting
- Uniklinik Köln
-
Contact:
- Maximilian Ruge, Prof. Dr.
-
München, Germany, 81377
- Recruiting
- Klinikum der Universität München
-
Contact:
- Niklas Thon, Prof. Dr.
-
Münster, Germany, 48149
- Recruiting
- Universitatsklinikum Munster
-
Contact:
- Walter Stummer, Prof. Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Biopsy proven, newly diagnosed, supratentorial, unifocal, lobar located IDH wild-type glioblastoma according to the criteria of the 2016 WHO classification.
- Not safely and/or not completely resectable, lobar located, unifocal, supratentorial IDH wild-type glioblastomas with a largest diameter ≤ 40 mm (largest diameter of the contrast enhanced tumor, as defined by enhanced T1 MRI sequences) are eligible in case of corresponding tumor board re-estimations.
- Potentially completely resectable, lobar located, unifocal, supratentorial, IDH wild-type glioblastoma with a largest diameter ≤ 40 mm are eligible in case of both patient's informed preference in favour of iPDT and corresponding tumor board recommendations.
- Age 18 - 70 years
- Karnofsky Performance status (KPS) of ≥ 70 %
- Minimal life expectancy of 3 months.
- Patients eligible for radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide: Adequate haematological function (Absolute neutrophil count (ANC) > 1.5 x 109/L, Platelet count > 100 x 109/L, Haemoglobin > 10 g/dL (may be transfused to maintain or exceed this level)).
- International normalized ratio (INR) or PT (secs) and activated partial thromboplastin time (aPTT) ≤ 1,5 times of the upper limit of normal in the laboratory where it was measured.
- Negative pregnancy test in fertile women
- For female and male patients of reproductive potential: Willingness to apply highly effective contraception (Pearl index <1) during the entire study.
Such methods include :
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
progestogen-only hormonal contraception associated with inhibition of ovulation :
- oral
- injectable
- implantable
- intrauterine device (IUD)
- intrauterine hormone-releasing system (IUS)
- bilateral tubal occlusion
- vasectomised partner
- sexual abstinence • Written informed consent has been signed and dated prior to or at the beginning of Visit -1
Exclusion criteria:
- Glioblastomas involving the basal ganglia, the corpus callosum, the primary motor cortex, the ventricular system, multifocal tumors, and those involving the brain stem and/or the cerebellum.
- Glioblastomas exceeding the 40 mm threshold in their largest diameter
- Simultaneous use of other potentially phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts)
- Hypersensitivity against porphyrins
- Known diagnosis of porphyria
- Acute or chronic hepatic diseases (levels of ASAT, ALAT and/or gamma-GT more than 2.5 times the upper limit of normal in the laboratory where it was measured)
- Manifest renal diseases with renal dysfunction (serum creatinine level > 1.5 times of the upper limit of normal in the laboratory where it was measured)
- Severe, active co-morbidity:
- Unstable angina and/or congestive heart failure within the last 6 months
- Transmural myocardial infarction within the last 6 months
- History of stroke, cerebral vascular accident, or transient ischemic attack within 6 months
- Serious and inadequately controlled cardiac arrhythmia
- Significant vascular disease (e.g. aortic aneurysm)
- Evidence of bleeding diathesis or coagulopathy
- Acute bacterial or fungal infections
- Acute exacerbation of chronic obstructive pulmonary disease
- Hepatic insufficiency resulting in clinical jaundice and/or coagulopathy
- Acquired immune deficiency syndrome; note, however, that HIV testing is not required for study entry.
- Inability to undergo MRI (e.g., presence of a pacemaker)
- Known intolerance to study medication
- Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent
- Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment or within 5 plasma half-life of the preceding study drug, whatever is longer.
- Pregnancy or breastfeeding
- In case of both complete absence of intra-operative fluorescence between any of the inserted light diffusers and absence of significant surgery-associated bleedings (i.e. light transmission is detectable between at least two of the inserted light diffusers), the tumor will be classified as 'fluorescence-negative tumor'. iPDT will however be performed. Regarding efficacy evaluation, patients with fluorescence-negative tumors will be excluded from PP-, but included in the ITT-evaluation, and will be evaluated regarding safety.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interstitial photodynamic therapy
20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
|
5-aminolevulinic acid powder for oral solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the incidence of treatment-emergent Adverse Events (safety and tolerability) of iPDT with PD L 506 in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma.
Time Frame: 2 weeks
|
The incidence of treatment-emergent Adverse Events (TEAEs) of CTC grades 3, 4 and 5 within two weeks following iPDT
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival rate at 12 months
Time Frame: 12 months
|
Percentage of patients without tumor progression 12 months after iPDT
|
12 months
|
Overall survival rate at 12 months
Time Frame: 12 months
|
Percentage of patients who are alive 12 months after iPDT
|
12 months
|
Progression-free survival
Time Frame: From date of iPDT until the date of first documented progression, up to 66 months
|
Time until first tumor progression
|
From date of iPDT until the date of first documented progression, up to 66 months
|
Overall survival
Time Frame: From date of iPDT until the date of death from any cause, up to 66 months
|
Time until death from any cause
|
From date of iPDT until the date of death from any cause, up to 66 months
|
MGMT promoter methylation status of the patient
Time Frame: Baseline
|
Analytical results for MGMT promoter methylation status (methylated/unmethylated) in the respective tumor samples of each patient
|
Baseline
|
Immune status of the patient
Time Frame: Baseline, 2 days, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Analytical results for immune parameters (PBMC, CD4+, CD8+) in the respective blood samples of each patient
|
Baseline, 2 days, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Results of investigator's assessment of patient's physical condition using Karnofsky performance status scale
Time Frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
To determine patient's physical condition using Karnofsky performance status scale ranging from 0% (worst outcome) to 100% (best outcome)
|
Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Results of investigator's assessment of patient's mental condition using Mini-mental State Examination
Time Frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
To determine patient's mental condition using Mini-mental State Examination scale ranging from 0 (worst outcome) to 30 (best outcome)
|
Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Results of investigator's assessment of patient's mental condition using National Institutes of Health Stroke Scale
Time Frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
To determine patient's mental condition using National Institutes of Health Stroke Scale ranging from 0 (best outcome) to 34 (worst outcome)
|
Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Results of investigator's assessment of patient's condition using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Questionnaire (QLQ-C30) together with the Brain module (BN20)
Time Frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
To determine patient's quality of life
|
Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months
|
Interstitial light transmittance and fluorescence data recorded
Time Frame: during iPDT treatment (up to 1 hour)
|
To determine whether correlations exist between length of OS/PFS and spectral online-monitoring measurement results (transmission and fluorescence measurements)
|
during iPDT treatment (up to 1 hour)
|
Interstitial fluorescence data recorded
Time Frame: during iPDT treatment (up to 1 hour)
|
To determine the rate of patients with fluorescence-negative tumors
|
during iPDT treatment (up to 1 hour)
|
Percentage of cylindrical diffusor laser probes without kinks, cracks etc. before and after iPDT for patients treated under protocol versions prior to V7.0
Time Frame: Day 0 (Treatment day), directly before and after iPDT
|
Assessing the safety and performance of the insertion of Cylindrical Diffusor Laser Probes into the brain for iPDT of brain tumors for patients treated under protocol versions prior to V7.0.
|
Day 0 (Treatment day), directly before and after iPDT
|
Percentage of guiding catheters without kinks, cracks etc. before and after iPDT
Time Frame: Day 0 (Treatment day), directly before and after iPDT
|
Assessing the safety and performance of the insertion of guiding catheters into the brain for iPDT of brain tumors
|
Day 0 (Treatment day), directly before and after iPDT
|
Percentage of iPDT treatments in which the laser system works properly as planned.
Time Frame: Day 0 (Treatment day), directly after iPDT
|
Assessing safety and performance of the laser system for iPDT of brain tumors.
|
Day 0 (Treatment day), directly after iPDT
|
Percentage of fibers/laser ports which show a maximum deviation in the output power of less than +/-10% to the pre-defined output power of 200 mW/cm diffusor length.
Time Frame: Day 0 (Treatment day), directly after iPDT
|
Assessing safety and performance of the combination of ML7710i laser system and Cylindrical Diffusor Laser Probes for the iPDT of brain tumors.
|
Day 0 (Treatment day), directly after iPDT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Niklas Thon, Prof. Dr., Klinikum der Universität München
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2021
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
March 1, 2027
Study Registration Dates
First Submitted
March 19, 2019
First Submitted That Met QC Criteria
March 28, 2019
First Posted (Actual)
April 1, 2019
Study Record Updates
Last Update Posted (Estimated)
November 16, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GL 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on 5-aminolevulinic acid
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
NorthShore University HealthSystemWithdrawn
-
medac GmbHCompletedBrain Cancer | Brain Tumors | Brain Tumor, Primary | Primary Brain Tumors | Cancer of Brain
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
St. Olavs HospitalOslo University Hospital; Norwegian University of Science and TechnologyCompletedCutaneous T-Cell Lymphoma, Unspecified | Chronic Graft Versus Host Disease in SkinNorway
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting
-
medac GmbHIKPCompleted
-
Southern Illinois UniversityDUSA Pharmaceuticals, Inc.CompletedBrain NeoplasmsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedGlioma | AstrocytomaUnited States
-
Andrew Sloan, MDCompletedBrain and Central Nervous System TumorsUnited States